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Abstract 
Objectives: We aimed to investigate BRAF V600E percentage immunohistochemically 
in ameloblastomas of a single institute cohort. We were interested if age, location, 
histological properties, or tumor recurrence depend on the BRAF status.  
Subjects, Materials and Methods: We had 36 formalin-fixed, paraffin-embedded 
ameloblastoma tissue samples of patients treated at the Helsinki University Hospital 
between the years 1983-2016. Tissue sections underwent immunohistochemistry by 
Ventana BenchMark XT immunostainer using Ms Anti-Braf V600E (VE1) MAB. We 
used R 3.4.2 and RSudio1.1.383 to conduct statistical analysis for BRAF positivity and 
earlier onset as well as tumor location. We used X² -tests and 2 by 2 table functions to 
determine connections between BRAF positivity and recurrence, growth pattern, and 
type.    
Results: BRAF positive tumors occurred in younger patients compared to BRAF 
negative tumors (p = 0.015) and they located mostly to the mandible (p = <0.001). 
Growth patterns were limited to two in BRAF negative tumors when BRAF positive 
tumors presented with one to four growth patterns (p = 0.02). None of the maxillary 
tumor showed BRAF positivity and of these, 72.2% recurred.  
Conclusions: An immunohistochemical BRAF marker could be a beneficial tool to 
predict the outcome of patients with this aggressive, easily recurring tumor.  
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INTRODUCTION 
Odontogenic tumors arise from the tooth forming apparatus. These are a highly heterogenic 
group of rare tumors originating from the cells of epithelial, ectomesenchymal, and, or 
mesenchymal elements occurring in the oro-maxillo-facial area. Ameloblastomas, clinically 
the most common odontogenic tumor, arise from the odontogenic epithelium and resembles 
histologically the dental enamel organ and the dental lamina. Ameloblastomas indicate dental 
integrity by expressing transcription factors of early dental epithelia, PITX2, MSX2, 
and DLX1, 2, 3, 4  (Heikinheimo et al., 2015). According to WHO, ameloblastomas are 
classified as ameloblastoma (intraosseus; solid/multicystic ameloblastoma), unicystic 
ameloblastoma, and peripheral ameloblastoma. Ameloblastomas grow in follicular, 
plexiform, acanthomatous, granular cell or basal cell patterns. (El-Naggar, Chan, Grandis, 
Takata, & Slootweg, 2017). In general, ameloblastomas are benign, locally invasive, and 
recurring tumors, usually located in the posterior portion of the mandible (80%), affecting 
people in all age groups (10 to 80 years), equally men and women. Due to the tumor’s high 
growth potential, patients may undergo severely mutilating surgery following difficult 
prosthetic treatments. 
Several studies have addressed the genetic background of ameloblastoma (Brown et al., 2014; 
Kurppa et al., 2014; Sweeney et al., 2014). Mutation in the mitogen-activated protein kinase 
(MAPK) pathway gene BRAF in which glutamic acid at codon 600 replaces the amino acid 
valine (V) has been found in 46-66% of solid or multicystic ameloblastomas, mainly in the 
mandible. The MAPK signaling pathway orchestrates cell proliferation, differentiation, 
migration, and survival. For example a BRAF mutation, commonly found in melanoma, 
thyroid, and colorectal cancers, leads to a constant activation of these functions (Holderfield, 
Deuker, McCormick, & McMahon, 2014). Activation of the MAPK pathway via BRAF has 
been suggested to function also in various odontogenic tumors with ameloblastomatous 
components, making the BRAFV600E a potential marker for diagnostic purposes (Brown et 
al., 2014; Brunner, Bihl, Jundt, Baumhoer, & Hoeller, 2015).  It has also been suggested that 
BRAF inhibitors could be a potential treatment modality for ameloblastomas. (Fernandes, 
Girardi, Bernardes, Fonseca, & Fregnani, 2018; Fregnani et al., 2017). BRAF mutated tumors 
locate more often to the mandible, and occur in younger patients. Ameloblastomas without 
BRAF mutations recure earlier and locate in the maxilla (Brown et al., 2014). Although 
reports of the genetic background of the development of ameloblastoma have emerged, the 
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exact mechanisms of cell differentiation, oncogenesis, and progression of this tumor remain 
unsolved (Nagi, Sahu, & Rakesh, 2016). 
Our study aimed to present the BRAF V600E immunohistochemical status in 36 
ameloblastomas from patients treated at Helsinki University Hospital (HUH) focusing on the 
following questions: which is the percentage of BRAF positivity, is age and tumor location a 
determining factor in BRAF-samples, does recurrence depend on BRAF-mutations, and does 
BRAF expression differ between histological or growth pattern variants.  
 
MATERIAL AND METHODS 
Patient and tissue material 
Patients treated at Department of Oral and Maxillofacial Diseases, HUH for ameloblastoma 
during 1983-2016 were included. There were 36 non-decalcified formalin-fixed, paraffin-
embedded whole tissue sample blocks available for examination. The tissue samples came 
from the archive of Department of Pathology, HUH, information on these specimens from Q-
pati registration files, and clinical data from the HUH’s patient archives and electronic patient 
records. The Finnish National Supervisory Authority for Welfare and Health (Valvira) 
granted permission for the use of patient samples. The Ethics Committee of Surgery and 
HUH’s Internal Review Board approved the study protocol (Dnro 151/13/03/02/2015).  
We have reported the clinical data and demographics of this cohort in detail in our previous 
publication (Kelppe et al., 2018). Of the 34 cases of our previous study, we had to discard 
four due to lack of tissue samples or because of tissue decalcification preventing the use of 
immunohistochemistry. To enlarge the cohort, six cases were added: four patients treated for 
a recurred tumor (primary tumor treated elsewhere) and two cases that were discarded from 
the previous study because of insufficient clinical data but having tissue available for this 
study, giving a total of 36 patients.   
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Immunohistochemistry 
Formalin-fixed, paraffin-embedded, 3µm thick tissue sections underwent automated 
immunohistochemistry by Ventana BenchMark XT immunostainer (Ventana Medical 
Systems, Tucson, AZ, USA) using Ms Anti-Braf V600E (VE1) Mab with a 32 minutes 
incubation time, Spring Bioscience diluted to 1:1500 and visualized by OptiView DAB 
IHCv3(Ventana) with amplification. The specimens were counterstained with haematoxylin. 
Melanoma tissue served as a positive control. In the negative control tissue the primary 
antibody was left out.  
 
Scoring of BRAF immunohistochemistry 
An oral pathologist (JK) examined the slides and considered cytoplasmic immunoreactivity 
as positive when present regardless of staining intensity (Fig.1.) The positivity was present 
only in tumoral tissue. Normal tissue was negative. 
 
Statistical analysis 
We calculated risk ratios for BRAF positive tumors and an earlier onset age as well as for 
BRAF positive tumors and location. We used X² -tests, and where relevant, 2 by 2 table 
functions to determine connections between BRAF positivity and recurrence, BRAF 
positivity and growth patterns, and BRAF positivity and ameloblastoma types. A p -value 
equal or less than 0.05 was considered significant. We used a logistic regression model with 
BRAF as an outcome variable to determine the odds ratio and the confidence interval for the 
location adjusted for gender and age. We conducted the analyses using R 3.4.2 (R Core Team 
2017) and RStudio 1.1.383. 
 
RESULTS 
Table 1. presents patient information. The male to female ratio was 1.25:1, men having an 
average age of 55.9 (range 13-83) and women 45.8 (range 18-71). Recurrence occurred (or 
the tumor was a recurrence to begin with) in 14 (38.9%) cases, 8 female and 6 male. Figure 1. 
presents recurrences occurring in maxillary and mandibular tumors.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
BRAF status 
BRAF positivity was found only in tumors located to the mandible (n = 26/36) (Table 1.). 
The average age of patients having a BRAF positive tumor was 46.8 and of those with a 
BRAF negative tumor 65.2. 
 
Mandible 
Of the studied ameloblastoma cases, 29 (80.6%) located to the mandible, of which 26 
(89.7%) were BRAF positive. Only 9 (31%) mandibular tumors recurred, all of them being 
BRAF positive. None of the mandibular BRAF negative tumors showed recurrence, though 
the amount of BRAF negative tumors was low (n = 3) (Table 1.). 
 
Maxilla 
Ameloblastoma occurred in the maxilla in 7 (19.4%) cases, all BRAF negative. Of maxillary 
tumors 5 (71.4%) recurred, 4 in male and 1 in a female patient (Table 1.). 
 
Histology 
Of ameloblastomas, 27 (75%) were solid/multicystic, 7 (19.4%) unicystic and 2 (5.5%) of 
peripheral type. In solid/muticystic ameloblastomas BRAF positivity occurred two times 
more often (18/27) than BRAF negativity (9/27). All unicystic ameloblastomas were BRAF 
positive. The over all mixture of growth patterns was versitile. Maxillary tumor seems to 
present more simple growth patter variations. BRAF positive tumors showed more variance 
in growth patterns (Figure 2.). Acanthomatosis was present in almost half (17/36) of all 
samples but BRAF negative tumors did not show acanthomatosis. Figure 3. presents 
examples of histology of BRAF positive and BRAF negative tumors. In BRAF positive 
tumors, the positivity seemed to vanish when desmoplasia was present (Figure 4.) 
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Statistics 
A relation between age and BRAF positivity was seen (p = 0.015) inclining that BRAF 
positive tumors occur earlier in life. In addition, a correlation between BRAF positive tumors 
and a mandibular location was seen (p = <0.001). None of the BRAF negative tumors had 
more than two growth patterns (p = 0.02). Nevertheless, recurrence or ameloblastoma type 
did not seem to be dependent on the BRAF status (Table 2.). In a logistic regression model, 
with BRAF+/- as outcome variable, adjusted for age and gender, odds ratio for location was 
2.32 (95% CI 1.77-3.05) indicating BRAF positive tumors to locate in the mandible.  
 
DISCUSSION 
Here we report BRAFV600E immunopositivity in our ameloblastoma material of 36 tumors. 
Previous studies show BRAF-mutation in more than 62.7% of ameloblastomas (Brown & 
Betz, 2015; Brown et al., 2014; Diniz et al., 2015; do Canto et al., 2019; Kurppa et al., 2014; 
Sweeney et al., 2014). Our results are in line with and further extend these findings, the 
corresponding proportion being 72.2% (26/36). Our cohort demonstrates male predominance 
in BRAF negative tumors, most of them located to the maxilla. Additionally, BRAF negative 
patients had an 18.4 years higher average age than the BRAF positive patients. Maxillary 
tumors of which all were BRAF negative, showed recurrence in 71.4% (5/7), while all 
recurring tumors in the mandible were BRAF positive (45%, 9/20). The overall recurrence 
rate, regardless of location, reached up to 38.9% (14/36). BRAF negative tumors 
demonstrated a simpler histologic scenery than the BRAF positive tumors.  
BRAF status is considered a predictive and prognostic tool for determining the course of 
ameloblastoma patients (Brown & Betz, 2015; Brown et al., 2014; Fregnani et al., 2017). 
BRAF inhibitors have even been used in treating ameloblastoma patients (Fernandes et al., 
2018). Distinct anatomical distribution between ameloblastomas carrying different alterations 
in SHH and MAPK pathways are rather indisputable: SMO mutations exists mainly in 
maxillary tumors and BRAF mutations in mandibular tumors (Brown et al., 2014; Sweeney et 
al., 2014). Our results are in line with these findings since all BRAF positive tumors were 
located to the mandible. Additionally, patients with a BRAF negative tumor were older than 
patients having a BRAF positive tumor as shown in previous works as well (Brown et al., 
2014). Brown et al. reported a mean age difference between patients with a BRAF negative 
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and BRAF positive tumors of 22.7 years (Brown & Betz, 2015), corresponding figure of the 
present study was 18.4 years. When regarding the overall average age of our patients, one 
must take into account the four cases of already recurred tumors increasing the average age. 
Although our material is limited, it seems that male predominance is present in maxillary, 
more often in recurring tumors. Instead in mandibular tumors the male to female ratio equal 
1:1.07, recurrence having female predominance (7/9 female and 2/9 male).  
BRAF positivity seemed to vary between different single growth patterns even though no 
assosciations came forth. In addition we found, that within a single tumor, the BRAF 
positivity seemed to diminish in desmoplastic areas. The reason for this finding remains 
unclear. Desmoplastic and plexiform ameloblastomas are the least likely tumors to recure 
(Hong et al., 2007). In this cohort, there was no solely desmoplastic tumors. Plexiform 
growth pattern often appeared with other growth patterns. Follicular, acanthomatous, and 
granular cell growth patterns were recurring most often in a study by Hong et al (2007). In 
our study, most tumors that recurred had plexiform and or follicular growth pattern. In our 
study tumors with only follicular growth pattern were BRAF positive. None of the tumors 
with three or more different growth patterns within one tumor was BRAF negative. 
Acanthomatosis occurred in 47.2 % of all ameloblastomas and all acanthomatous tumors 
were BRAF positive. The reason for this can only be speculated. Both recurring and non-
recurring tumors presented with all histological growth patterns. In addition, all unicystic 
ameloblastomas were BRAF positive being in line with research done by Heikinheimo et. al 
in which they speculate unicystic ameloblastoma and ameloblastoma possibly being a part of 
the spectrum of the same disease (Heikinheimo et al., 2019).  
It has been discussed that immunohistochemistry for identifying BRAFV600E mutated 
protein from formalin-fixed, paraffin-embedded samples is reliable compared to molecular 
techniques, thus making it a beneficial tool to detect these mutations as part of the normal 
diagnostic (Brown et al., 2014; Capper et al., 2011). Recently also opposite results have 
emerged (Szymonek et al., 2017). Decalcification with formic acid however affects 
immunoreactivity. When preparing a tumor sample for normal diagnostic examination, these 
aspects should be taken into consideration. 
A larger patient cohort could have provided a more reliable statistical analysis. In addition, 
some samples were over 30 years old which might affect the staining intensity. On the other 
hand, it was surprising how well immunohistochemistry functioned on older samples. In 
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some cases, biopsies or other suboptimal samples were the only usable tissue which makes 
growth pattern examination hard and less reliable.  
To conclude: our study confirms the previous results on BRAF positivity compared with 
location and age of ameloblastoma patients. The clinical use of BRAF immunohistochemistry 
applied on a representable tissue sample, could give beneficial information in diagnosis and 
surgical management. 
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 TABLES 
Table 1. Tumor BRAF-expression distribution between mandibula and maxilla and between 
male and female patients. Average age of patients with BRAF positive and BRAF negative is 
also shown. The total ameloblastoma count was 36. 
  
BRAF+ BRAF- 
  
Mandibula 29/36 (80,6%) 26/29 (89,7%) 3/29 (10,3%) 
Male 14/29(48,3%) 12/29 (41,4%) 2/29 (6,9%) 
Female 15/29(51,7%) 14/29 (48,3%) 1/29 (3,4%) 
Recurrence 9/29 (31%) 9/29 (31%) 0/29 (0%) 
No recurrence 20/29 (69%) 17/29 (58,6%) 3/29 (10,3%) 
    Maxilla 7 /36(19,4%) 0/7(0%) 7/7(100%) 
Male 6/7 (85,7%) 0 6/7 (85,7%) 
Female 1/7 (14,3%) 0 1/7 (14,3%) 
Recurrence 5/7 (71,4%) 0 5/7 (71,4%) 
No recurrence 2/7 (28,6) 0 2/7 (28,6) 
    Age (avarage, 
years) 51,9 46,8 65,2 
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Table 2. 2 by 2 tables for BRAF and median age, recurrance and location. 
  BRAF+ BRAF- Total X² test; p-value 
      
Median age  
Lower age group 17 2 19 
X²=5.969, p-value: 0.015 
Higher age group 9 8 17 
  26 10 36  
      
Recurrence 
Yes 17 5 22 
X²=0.21758, p-value: 0.6409 
No 9 5 14 
  26 10 36  
      
Location 
Mandibula 26 3 29 
X²=22.593, p-value: <0.001 
Maxilla 0 7 7 
  26 10 36  
 
 
 
Figure 1. Mandibula-maxillary distribution among male and female patients regarding 
recurrence. Almost every other mandibular tumor in female patients recurred. In male 
patients with maxillary tumors every other tumor recurred. 
Figure 2. presenting different histologic growth pattern variations in BRAF positive (orange) 
and BRAF negative (blue) samples. BRAF negative tumors lacked purely follicular growth 
patterns, never showed more than two growth patterns and never showed acanthomatous 
metaplasia. 
Figure 3. BRAF positivity shown in mandibular tumors. Mandibular tumors (a,e) and the HE 
staining of the same tumors (b,f). BRAF negativity in maxillary tumors (c,g) and HE staining 
of these cases (d,h). (Magnification x100) 
Figure 4. Follicular or plexiform patterns demonstrate BRAF positivity (a-d). Where 
desmoplasia is present the tumor seems to lose its round shape and BRAF positivity 
diminishes. In a x40 magnification little dots of positivity is never the less observed.  
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